Biocept, Inc. (NASDAQ:BIOC) Q3 2022 Earnings Call Transcript

Sam Riccitelli: So we’re seeing relatively good performance there. I don’t have any off-hand statistics for that other than track — you can track the number of physicians who order every quarter. You can attract — you can also track the trends — the positive trends that we’re seeing in cases per client that’s been steadily increasing. So those kinds of metrics are all contained in our investor deck. So those kinds of things give us great assurance that the test is sticky once the clinicians have some experience with it.

Kemp Dolliver: Great. Thank you, Sam.

Sam Riccitelli: Thank you, Kemp. Thanks for the questions.

Operator: And this will conclude our question-and-answer session. I’d like to turn the conference back over to Sam Riccitelli for any closing remarks.

Sam Riccitelli: Once again, I’d like to thank everyone for participating on today’s call and for your interest in Biocept. We look forward to providing an update during our next conference call in March 2023 when we report our 2022 fourth quarter and full year financial results. Thanks again, and have a great day.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect your lines at this time.